Tesamorelin 10mg Research Peptide
Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH) consisting of the full 44-amino acid sequence of endogenous GHRH with a stabilizing trans-3-hexenoic acid group attached to the N-terminus. It stimulates the pituitary gland to produce and secrete endogenous growth hormone through natural pulsatile patterns, distinguishing it mechanistically from exogenous GH administration. This 10mg vial provides research-grade tesamorelin at ≥99% purity, HPLC and MS/MS verified per batch.
Research Background
Tesamorelin is unique among GHRH analogues in having received FDA approval — it was approved in 2010 under the brand name Egrifta for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. Phase 3 trials demonstrated 15–18% visceral adipose tissue reduction over 26 weeks. A 2021 randomized trial found tesamorelin improved verbal memory and executive function in older adults with mild cognitive impairment — the first GHRH analogue to demonstrate cognitive improvement in a controlled trial.
For the full breakdown of tesamorelin’s mechanism, FDA approval data, cognitive research findings, and dosage reference, see our Tesamorelin Research Guide. Also available in 20mg.
Compound Specifications
- Format: Lyophilized powder
- Purity: ≥99% (HPLC verified)
- Quantity: 10mg per vial
- Storage: −20°C, protected from light
- Molecular Weight: 5135.9 Da
Certificate of Analysis
All tesamorelin vials are third-party tested by independent ISO-certified laboratories. HPLC and MS/MS validation performed per batch. COA available on request.
For research and laboratory use only. Not for human consumption. Not intended to diagnose, treat, cure, or prevent any disease.
